公开(公告)号：US11246939B2

公开(公告)日：2022-02-15

申请号：US16573351

申请日：2019-09-17

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Sun Hwa Kim ,  Ick Chan Kwon ,  In-San Kim ,  Kwangmeyung Kim ,  Yoosoo Yang ,  Young-Ji Ko

IPC: A61K47/55 ,  A61K47/54 ,  A61K31/713 ,  C12N15/113 ,  C07K14/705 ,  A61P35/00 ,  A61K38/00

Abstract: A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.

公开(公告)号：US11015197B2

公开(公告)日：2021-05-25

申请号：US16425849

申请日：2019-05-29

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Sun Hwa Kim ,  Ick Chan Kwon ,  Kwangmeyung Kim ,  Hong Yeol Yoon ,  Gi-Jung Kwak ,  Juho Park

IPC: C12N15/113 ,  A61P35/00

Abstract: The present invention relates to a novel anti-miRNA single-stranded nucleic acid maleimide derivative, which comprises an anti-miRNA single-stranded nucleic acid having a nucleic acid sequence complementary to a nucleic acid sequence of an miRNA. Further, the present invention provides an anti-miRNA single-stranded nucleic acid-serum albumin conjugate in which serum albumin is covalently bonded to the anti-miRNA single-stranded nucleic acid maleimide derivative via the maleimide group.

公开(公告)号：US10905774B2

公开(公告)日：2021-02-02

申请号：US16247937

申请日：2019-01-15

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gi Hoon Nam ,  Eun Jung Lee ,  Yoo Soo Yang ,  Cherl Hyun Jeong ,  In-San Kim ,  Kwangmeyung Kim

IPC: A61K39/00 ,  A61K47/00 ,  A61K9/14 ,  A61K39/12 ,  A61K47/69 ,  A61K31/704 ,  C07K14/79 ,  C07K14/47 ,  A61K31/69 ,  A61K9/51 ,  A61K39/395 ,  A61P35/00 ,  A61K31/337 ,  B82Y5/00 ,  B82Y40/00 ,  C07K14/005 ,  C07K14/705 ,  C07K14/785 ,  C07K16/28

Abstract: The present invention relates to a novel recombinant nanocage and use thereof wherein the nanocage is formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and to a protein nanocage complex in which an immunogenic cell death inducer is loaded in the nanocage as an active ingredient.

公开(公告)号：US11833204B2

公开(公告)日：2023-12-05

申请号：US17529450

申请日：2021-11-18

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  In-Cheol Sun ,  Man Kyu Shim ,  Ji Woong Choi

IPC: A61K31/351 ,  A61K41/00 ,  A61P35/00 ,  A61K47/69

CPC classification number: A61K41/0076 ,  A61K31/351 ,  A61K47/6929 ,  A61P35/00

Abstract: Disclosed are visible light-activatable antitumor self-assembled nanoparticles or antitumor immunity-inducing self-assembled nanoparticles. The self-assembled nanoparticles induce potent apoptosis in cancer cells and increase their own anticancer immunogenicity, thereby maximizing their therapeutic efficacy for cancer.

公开(公告)号：US10213515B2

公开(公告)日：2019-02-26

申请号：US15169493

申请日：2016-05-31

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  Ju Hee Ryu ,  Ick Chan Kwon ,  Man Kyu Shim ,  Hong Yeol Yoon

IPC: A61K51/00 ,  A61M36/14 ,  A61K49/00 ,  C07K9/00 ,  G01N33/574 ,  G01N33/58 ,  C07K5/11 ,  C07K5/107 ,  A61K47/54

Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.

公开(公告)号：US10206987B2

公开(公告)日：2019-02-19

申请号：US15299993

申请日：2016-10-21

Applicant: Korea University Research And Business Foundation ,  Korea Institute of Science and Technology

Inventor： Jeewon Lee ,  Bo Ram Lee ,  Kwangmeyung Kim ,  Ju Hee Ryu ,  Ho Kyung Ko

IPC: A61K39/00 ,  A61K9/14 ,  B82Y5/00

Abstract: The present invention relates to a protein nanoparticle having a surface on which a cancer-specific epitope is fused and expressed, a method for producing the same, and a composition for cancer immunotherapy containing the protein nanoparticle as an active ingredient, and more specifically, to a recombinant microorganism into which a vector in which a promoter, a gene of a human ferritin heavy chain protein, and a gene encoding the cancer-specific epitope are operably linked is introduced, a protein nanoparticle in which a cancer-specific epitope is fused and expressed on a surface of the human ferritin heavy chain protein, a method of producing the protein nanoparticle, and a composition for cancer immunotherapy including the protein nanoparticle as the active ingredient, wherein the cancer-specific epitope on the surface of the protein nanoparticle according to the present invention is able to be expressed with correct orientation and high density, and the composition for cancer immunotherapy including the protein nanoparticle as the active ingredient has significantly excellent cancer immunotherapeutic effect as compared to the existing nanoparticle-based composition.

公开(公告)号：US11498946B2

公开(公告)日：2022-11-15

申请号：US17118767

申请日：2020-12-11

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  Ju Hee Ryu ,  Hong Yeol Yoon ,  Man Kyu Shim ,  Suah Yang

IPC: C07K14/47 ,  A61P35/00 ,  A61K47/10 ,  C07K16/28 ,  A61K47/64

Abstract: The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.
In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.

公开(公告)号：US20190216947A1

公开(公告)日：2019-07-18

申请号：US16247937

申请日：2019-01-15

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gi Hoon NAM ,  Eun Jung Lee ,  Yoo Soo Yang ,  Cherl Hyun Jeong ,  In-San Kim ,  Kwangmeyung Kim

IPC: A61K47/69 ,  B82Y5/00 ,  C07K16/28 ,  B82Y40/00 ,  A61K31/704 ,  A61P35/00 ,  C07K14/785 ,  C07K14/79 ,  C07K14/705 ,  C07K14/005 ,  A61K31/337

CPC classification number: A61K47/6929 ,  A61K9/51 ,  A61K31/337 ,  A61K31/69 ,  A61K31/704 ,  A61K39/395 ,  A61P35/00 ,  B82Y5/00 ,  B82Y40/00 ,  C07K14/005 ,  C07K14/47 ,  C07K14/70546 ,  C07K14/785 ,  C07K14/79 ,  C07K16/2818

Abstract: The present invention relates to a novel recombinant nanocage and use thereof wherein the nanocage is formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and to a protein nanocage complex in which an immunogenic cell death inducer is loaded in the nanocage as an active ingredient.

公开(公告)号：US20170112910A1

公开(公告)日：2017-04-27

申请号：US15299993

申请日：2016-10-21

Applicant: Korea University Research And Business Foundation ,  Korea Institute of Science and Technology

Inventor： Jeewon Lee ,  Bo Ram Lee ,  Kwangmeyung Kim ,  Ju Hee Ryu ,  Ho Kyung Ko

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K9/5169 ,  A61K2039/55555 ,  A61K2039/6031 ,  B82Y5/00

Abstract: The present invention relates to a protein nanoparticle having a surface on which a cancer-specific epitope is fused and expressed, a method for producing the same, and a composition for cancer immunotherapy containing the protein nanoparticle as an active ingredient, and more specifically, to a recombinant microorganism into which a vector in which a promoter, a gene of a human ferritin heavy chain protein, and a gene encoding the cancer-specific epitope are operably linked is introduced, a protein nanoparticle in which a cancer-specific epitope is fused and expressed on a surface of the human ferritin heavy chain protein, a method of producing the protein nanoparticle, and a composition for cancer immunotherapy including the protein nanoparticle as the active ingredient, wherein the cancer-specific epitope on the surface of the protein nanoparticle according to the present invention is able to be expressed with correct orientation and high density, and the composition for cancer immunotherapy including the protein nanoparticle as the active ingredient has significantly excellent cancer immunotherapeutic effect as compared to the existing nanoparticle-based composition.